Navigation Links
Regeneron Announces September 2009 Investment Conference Presentations

TARRYTOWN, N.Y., Sept. 10 /PRNewswire-FirstCall/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast management presentations that are scheduled for delivery later this month at the following investment conferences:

  • The Morgan Stanley Global Healthcare Unplugged Conference at 8:00 a.m. Eastern Time on Tuesday, September 15
  • The NewsMakers in the Biotech Industry Conference at 9:00 a.m. Eastern Time on Wednesday, September 16
  • The ThinkEquity Annual Growth Conference at 2:00 p.m. Eastern Time on Thursday, September 17
  • The UBS Global Life Sciences Conference at 9:00 a.m. Eastern Time on Monday, September 21

The presentation at the Morgan Stanley Global Healthcare Unplugged Conference will be a conversation with Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron, and a Morgan Stanley analyst. The presentations at the other conferences will provide an overview of the Company, including its three Phase 3 clinical programs.

The sessions may be accessed through the Company's web site,, on the Investor Relations page under the Presentations heading. Archived versions of the presentations will be available for thirty days after the live webcasts. Additional information about Regeneron and recent news releases are available on the Regeneron web site.

Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions. In addition to ARCALYST(R) (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, inflammatory diseases, and pain, and has preclinical programs in other diseases and disorders.

    Contact Information:
    Peter Dworkin                   Laura Lindsay
    Investor Relations              Media Relations
    914.345.7640                    914.345.7800

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Amedica Announces New Global Headquarters
2. Major Rollback of Pharmaceutical Bench Mark Prices Approved by Federal Court of Appeals, Hagens Berman Announces
3. TEDIndia Announces List of Inspiring Speakers from Across the Globe
4. Inverness Medical Innovations Announces September Investor Conference Schedule
5. JHD Group Announces TURNKEY EHR(TM) Service
6. SXC Health Solutions announces PBM contract renewal with Hawaii Employer-Union Health Benefits Trust Fund
7. VirtualHealth Technologies Announces Secure eHealth Agreement With DRM Security to Market Secure Document Courier and Storage Platform
8. Patriot Scientific Corporation Announces Alcon Inc.s Purchase of a Moore Microprocessor Patent(TM) Portfolio License
9. QuatRx Announces Positive Results of Second Pivotal Phase 3 Clinical Study for Ophena(TM) (Ospemifene Tablets) in Treatment of Postmenopausal Vaginal Atrophy
10. NBTY To Web Cast Presentation at CL King Best Ideas Conference; Announces Preliminary Unaudited Net Sales Results For August 2009
11. Sambazon Announces Scientific Advisory Board
Post Your Comments:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... was developed to enhance the health of felines. The formula is all-natural and is ... herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs ... College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. ... treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/24/2016)... , ... June 24, 2016 , ... A recent ... most people are unfamiliar with. The article goes on to state that individuals are ... many of these less common operations such as calf and cheek reduction. The Los ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Scientific Sessions in Dallas that it will receive two significant new grants to ... came as PHA marked its 25th anniversary by recognizing patients, medical professionals and ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... Australia,s successful biotechnology scientists, Dr Graham ... Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). Noxopharm is seeking ... ASX. Noxopharm is a clinic-ready company with its first ... study later this year. NOX66 ... cancer patients - the ability of cancers to become resistant to ...
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) announced ... Act of 1976, as amended ("HSR"), with respect to ... CPXX ) expired effective June 24, 2016, ... previously announced on May 31, 2016, Jazz Pharmaceuticals and ... Jazz Pharmaceuticals has commenced a tender offer for all ...
(Date:6/26/2016)... June 27, 2016  VMS Rehab Systems, Inc. ( ... take whatever measures required to build a strong and ... is currently listed on the OTC Markets-pink current trading ... and CEO, "We are seeing an anomaly in market ... not only by the Company, but shareholders and market ...
Breaking Medicine Technology: